Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,075 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
Domingo P, Suárez-Lozano I, Torres F, Teira R, Lopez-Aldeguer J, Vidal F, Muñoz A, Viciana P, Lozano F, Vergara A, Roca B, García Alcalde ML, Cosín J, Terrón A, Galindo MJ, Geijo P, Ribera E, Gonzalez J, Sanchez T, Lacalle JR, Garrido M. Domingo P, et al. Among authors: vidal f. J Antimicrob Chemother. 2008 Jun;61(6):1348-58. doi: 10.1093/jac/dkn121. Epub 2008 Mar 20. J Antimicrob Chemother. 2008. PMID: 18356150 Clinical Trial.
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.
Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, Sánchez de la Rosa R, Giralt M, Alvarez ML, López-Dupla M, Torres F, Villarroya F, Cihlar T, Domingo P. Vidal F, et al. Antimicrob Agents Chemother. 2006 Nov;50(11):3824-32. doi: 10.1128/AAC.00437-06. Epub 2006 Aug 28. Antimicrob Agents Chemother. 2006. PMID: 16940060 Free PMC article.
Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy.
Gutiérrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, Hernández-Quero J, Alemán R, Vidal F, Salavert M, Blanco JR, Leal M, Dronda F, Perez Hoyos S, del Amo J; CoRIS-MD. Gutiérrez F, et al. Among authors: vidal f. Curr HIV Res. 2008 Mar;6(2):100-7. doi: 10.2174/157016208783885038. Curr HIV Res. 2008. PMID: 18336257
Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality.
Alvarez-Martínez MJ, Moreno A, Miró JM, Valls ME, Rivas PV, de Lazzari E, Sued O, Benito N, Domingo P, Ribera E, Santín M, Sirera G, Segura F, Vidal F, Rodríguez F, Riera M, Cordero ME, Arribas JR, Jiménez de Anta MT, Gatell JM, Wilson PE, Meshnick SR; Spanish PCP Working Group. Alvarez-Martínez MJ, et al. Among authors: vidal f. Diagn Microbiol Infect Dis. 2008 Sep;62(1):34-43. doi: 10.1016/j.diagmicrobio.2008.04.016. Epub 2008 Jun 12. Diagn Microbiol Infect Dis. 2008. PMID: 18554841
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Crespo M, Ribera E, Suárez-Lozano I, Domingo P, Pedrol E, López-Aldeguer J, Muñoz A, Viladés C, Sánchez T, Viciana P, Teira R, García-Alcalde ML, Vergara A, Lozano F, Galindo MJ, Cosin J, Roca B, Terrón A, Geijo P, Vidal F, Garrido M; VACH Cohort Study Group. Crespo M, et al. Among authors: vidal f. J Antimicrob Chemother. 2009 Jan;63(1):189-96. doi: 10.1093/jac/dkn450. Epub 2008 Nov 6. J Antimicrob Chemother. 2009. PMID: 18988678 Clinical Trial.
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari Ed, Gatell JM; ATAZIP Study Group. Mallolas J, et al. Among authors: vidal f. J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36. doi: 10.1097/QAI.0b013e31819a226f. J Acquir Immune Defic Syndr. 2009. PMID: 19390327 Clinical Trial.
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, Ribera E, Knobel H, Roca V, Gutiérrez F, Blanco JL, Mallolas J, Llibre JM, Clotet B, Dalmau D, Segura F, Arribas JR, Cosín J, Barrufet P, Casas E, Ferrer E, Curran A, González A, Pich J, Cruceta A, Arnaiz JA, Miró JM, Gatell JM; BICOMBO Study Team. Martínez E, et al. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):290-7. doi: 10.1097/QAI.0b013e3181aa12d5. J Acquir Immune Defic Syndr. 2009. PMID: 19398921 Clinical Trial.
Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy.
Domingo P, Suarez-Lozano I, Torres F, Pomar V, Ribera E, Galindo MJ, Cosin J, Garcia-Alcalde ML, Vidal F, Lopez-Aldeguer J, Roca B, Gonzalez J, Lozano F, Garrido M; VACH Cohort Study Group. Domingo P, et al. Among authors: vidal f. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):582-7. doi: 10.1097/QAI.0b013e3181adcb01. J Acquir Immune Defic Syndr. 2009. PMID: 19512939
1,075 results